RxDoctor Payments Data

Arutyun Topsakalyan, MD

General Practice · Glendale, CANPI 1205906310

Payments from drug & device makers

$5,020in general payments, 2019–2025

Across 240 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Amarin Pharma, Inc.$796
  • Boehringer Ingelheim$574
  • Johnson & Johnson$307
  • Astellas Pharma US Inc$202
  • plus $577 from 10 others

What the payments were for

  • Food & beverage$5,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,020 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$9,522,559
Medicare patients
893
Services billed
13,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide934$491,763
CreonLipase/Protease/Amylase489$415,837
VascepaIcosapent Ethyl1,274$412,842
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate399$341,319
OzempicSemaglutide352$330,567
JanumetSitagliptin Phos/Metformin Hcl426$250,762
MyrbetriqMirabegron466$209,274
Diclofenac Sodium1,053$203,794
XareltoRivaroxaban278$174,676
Dexlansoprazole DrDexlansoprazole957$167,565
SynjardyEmpagliflozin/Metformin Hcl268$164,769
EliquisApixaban270$160,512
Icosapent Ethyl927$157,424
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag139$156,130
Tavaborole139$151,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Restasis, Namzaric, Ubrelvy$1,442$1,180,2561,838 claims
Boehringer IngelheimSynjardy, Jardiance, Tradjenta$574$351,244584 claims
Novo NordiskOzempic$185$330,567352 claims
Astellas Pharma US IncMyrbetriq$202$209,274466 claims
GSKTrelegy Ellipta, Breo Ellipta$102$206,135385 claims
Johnson & JohnsonXarelto$307$174,676278 claims
PfizerEliquis$22$160,512270 claims
AstraZenecaFarxiga, Brilinta$70$123,718237 claims
NovartisEntresto$28$94,293133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →